Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.

Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, Geurts JJG, Rocca MA, Sastre-Garriga J, Enzinger C, de Stefano N, Filippi M, Rovira Á, Barkhof F, Vrenken H; MAGNIMS Study Group.

Neuroimage Clin. 2018 Apr 26;19:466-475. doi: 10.1016/j.nicl.2018.04.023. eCollection 2018. Review.

2.

Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O.

Brain. 2018 Jun 1;141(6):1665-1677. doi: 10.1093/brain/awy088.

3.

Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.

Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M; MAGNIMS Study Group.

Radiology. 2018 May 27:172468. doi: 10.1148/radiol.2018172468. [Epub ahead of print]

PMID:
29714673
4.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N; Jacqueline Palace on behalf of the MAGNIMS study group.

Nat Rev Neurol. 2018 Mar 20;14(4):213. doi: 10.1038/nrneurol.2018.39.

PMID:
29582852
5.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213. doi: 10.1038/nrneurol.2018.14. Epub 2018 Mar 9. Review. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213.

PMID:
29521337
6.

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T; MAGNIMS study group.

Neurosci Biobehav Rev. 2018 Jun;89:85-98. doi: 10.1016/j.neubiorev.2018.02.012. Epub 2018 Feb 23. Review.

PMID:
29477616
7.

Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.

Camara-Lemarroy CR, Castilló J, Sastre-Garriga J, Tintore M, Montalban X.

Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185. [Epub ahead of print]

PMID:
29473796
8.

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X.

Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006.

PMID:
29462277
9.

[Remodelling of the Scientific Committee and a new series of neuroepidemiology reviews].

Sastre-Garriga J, Otero-Romero S.

Rev Neurol. 2018 Feb 16;66(4):103. Spanish.

10.

Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis.

Pareto D, Sastre-Garriga J, Alonso J, Galán I, Arévalo MJ, Renom M, Montalban X, Rovira À.

J Neuroimaging. 2018 May;28(3):313-319. doi: 10.1111/jon.12500. Epub 2018 Feb 5.

PMID:
29400912
11.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

12.

Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.

Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O.

Nat Rev Neurol. 2018 Feb;14(2):75-93. doi: 10.1038/nrneurol.2017.171. Epub 2018 Jan 12. Review.

PMID:
29326424
13.

"Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - NO.

Sastre-Garriga J.

Mult Scler. 2018 Apr;24(5):576-577. doi: 10.1177/1352458517751648. Epub 2018 Jan 10. No abstract available.

PMID:
29318919
14.

Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.

Aymerich FX, Auger C, Alonso J, Alberich M, Sastre-Garriga J, Tintoré M, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2018 Feb;39(2):399-404. doi: 10.3174/ajnr.A5495. Epub 2017 Dec 28.

PMID:
29284602
15.

[Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].

Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X.

Rev Neurol. 2018 Jan 1;66(1):25-32. Review. Spanish.

16.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X.

Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.

17.

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A.

Mult Scler. 2017 Oct 1:1352458517735191. doi: 10.1177/1352458517735191. [Epub ahead of print]

PMID:
28984163
18.

Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.

de Sitter A, Steenwijk MD, Ruet A, Versteeg A, Liu Y, van Schijndel RA, Pouwels PJW, Kilsdonk ID, Cover KS, van Dijk BW, Ropele S, Rocca MA, Yiannakas M, Wattjes MP, Damangir S, Frisoni GB, Sastre-Garriga J, Rovira A, Enzinger C, Filippi M, Frederiksen J, Ciccarelli O, Kappos L, Barkhof F, Vrenken H; MAGNIMS study group and for neuGRID.

Neuroimage. 2017 Dec;163:106-114. doi: 10.1016/j.neuroimage.2017.09.011. Epub 2017 Sep 9.

PMID:
28899746
19.

Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.

Preziosa P, Rocca MA, Mesaros S, Meani A, Montalban X, Drulovic J, Droby A, Zipp F, Calabrese M, Sastre-Garriga J, Dujmovic-Basuroski I, Rovira A, Filippi M.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):316-318. doi: 10.1136/jnnp-2017-315863. Epub 2017 Jul 19. No abstract available.

PMID:
28724720
20.

Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis.

Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X.

AJNR Am J Neuroradiol. 2017 Aug;38(8):1486-1493. doi: 10.3174/ajnr.A5253. Epub 2017 Jun 15.

PMID:
28619842
21.

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2018 May;24(6):721-727. doi: 10.1177/1352458517707070. Epub 2017 Apr 26.

PMID:
28445084
22.

Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects.

Sastre-Garriga J, Pareto D, Rovira À.

Neuroimaging Clin N Am. 2017 May;27(2):289-300. doi: 10.1016/j.nic.2017.01.002. Epub 2017 Feb 20. Review.

PMID:
28391787
23.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M.

Mult Scler. 2018 Mar;24(3):301-312. doi: 10.1177/1352458517697830. Epub 2017 Mar 16.

PMID:
28301287
24.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.

Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.

PMID:
28287331
25.

[New areas, new challenges...]

Sastre-Garriga J.

Rev Neurol. 2017 Mar 1;64(5):193. Spanish. No abstract available.

26.

Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images.

Vidal-Jordana A, Pareto D, Sastre-Garriga J, Auger C, Ciampi E, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2017 Feb;38(2):250-256. doi: 10.3174/ajnr.A4999. Epub 2016 Nov 24.

27.

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X.

Neurology. 2016 Sep 27;87(13):1368-74. doi: 10.1212/WNL.0000000000003144. Epub 2016 Aug 26.

PMID:
27566747
28.

Neurofilament light chain level is a weak risk factor for the development of MS.

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M.

Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12. Erratum in: Neurology. 2016 Nov 8;87(19):2068.

29.

Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI.

Aymerich FX, Auger C, Alcaide-Leon P, Pareto D, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Montalban X, Rovira A.

Eur Radiol. 2017 Apr;27(4):1361-1368. doi: 10.1007/s00330-016-4503-3. Epub 2016 Jul 25.

PMID:
27456965
30.

Multiple sclerosis: Dimethyl fumarate is coming of age.

Tintoré M, Sastre-Garriga J.

Nat Rev Neurol. 2016 Aug;12(8):436-7. doi: 10.1038/nrneurol.2016.106. Epub 2016 Jul 22. No abstract available.

PMID:
27448183
31.

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X.

Mult Scler. 2017 Apr;23(4):556-566. doi: 10.1177/1352458516656808. Epub 2016 Jul 11.

PMID:
27354019
32.

[A message from the new Editor of the Revista de Neurologia].

Sastre-Garriga J.

Rev Neurol. 2016 Jun 16;62(12):529. Spanish. No abstract available.

33.

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X.

Mult Scler. 2016 Oct;22(11):1386-1396. Epub 2016 May 19. Review.

PMID:
27207462
34.

Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected?

Sastre-Garriga J.

Mult Scler. 2016 Jun;22(7):975-6. doi: 10.1177/1352458516644677. Epub 2016 Apr 18.

PMID:
27207451
35.

Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response.

Comabella M, Sastre-Garriga J, Montalban X.

Curr Opin Neurol. 2016 Jun;29(3):254-62. doi: 10.1097/WCO.0000000000000336. Review.

PMID:
27075495
36.

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.

Midaglia L, Juega Mariño JM, Sastre-Garriga J, Rovira A, Vidal-Jordana A, López-Pérez MA, Marzo-Sola ME, Librada Escribano F, Montalban X.

Mult Scler. 2016 May;22(6):842-6. doi: 10.1177/1352458516638557. Epub 2016 Mar 18.

PMID:
26993120
37.

Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X.

J Neuroimaging. 2016 Sep;26(5):532-8. doi: 10.1111/jon.12337. Epub 2016 Mar 2.

PMID:
26935253
38.

Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load.

Pareto D, Sastre-Garriga J, Aymerich FX, Auger C, Tintoré M, Montalban X, Rovira A.

Neuroradiology. 2016 May;58(5):467-74. doi: 10.1007/s00234-016-1654-5. Epub 2016 Feb 4.

PMID:
26847633
39.

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group.

Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26. Review.

40.

Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling.

Valverde S, Oliver A, Roura E, Pareto D, Vilanova JC, Ramió-Torrentà L, Sastre-Garriga J, Montalban X, Rovira À, Lladó X.

Neuroimage Clin. 2015 Oct 28;9:640-7. doi: 10.1016/j.nicl.2015.10.012. eCollection 2015.

41.

Highlights from the 31st ECTRIMS congress - Barcelona 2015.

Sastre-Garriga J, Wiendl H.

Mult Scler. 2016 Jan;22(1):7-10. doi: 10.1177/1352458515620500. No abstract available.

PMID:
26684283
42.

Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.

Enzinger C, Pinter D, Rocca MA, De Luca J, Sastre-Garriga J, Audoin B, Filippi M.

Mult Scler. 2016 Mar;22(3):269-78. doi: 10.1177/1352458515619781. Epub 2015 Dec 18. Review.

PMID:
26683590
43.

Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe.

Otero-Romero S, Ramió-Torrentà L, Pericot I, Carmona O, Perkal H, Saiz A, Bufill E, Robles R, Simón E, Llufriu S, Vaqué-Rafart J, Sastre-Garriga J, Montalban X.

J Neurol Sci. 2015 Dec 15;359(1-2):146-50. doi: 10.1016/j.jns.2015.10.042. Epub 2015 Oct 28.

PMID:
26671104
44.

Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis.

Pareto D, Sastre-Garriga J, Auger C, Vives-Gilabert Y, Delgado J, Tintoré M, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2015 Dec;36(12):2270-6. doi: 10.3174/ajnr.A4485. Epub 2015 Oct 8.

45.

Predictive value of early brain atrophy on response in patients treated with interferon β.

Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e132. doi: 10.1212/NXI.0000000000000132. eCollection 2015 Aug.

46.

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X.

J Neurol. 2015 Dec;262(12):2617-26. doi: 10.1007/s00415-015-7798-0. Epub 2015 Jun 5. Review.

PMID:
26041617
47.

Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X.

Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21.

PMID:
25902415
48.

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Negrotto L, Tur C, Tintoré M, Arrambide G, Sastre-Garriga J, Río J, Comabella M, Nos C, Galán I, Vidal-Jordana A, Simon E, Castilló J, Palavra F, Mitjana R, Auger C, Rovira À, Montalban X.

Mult Scler. 2015 Dec;21(14):1802-10. doi: 10.1177/1352458515575338. Epub 2015 Mar 16.

PMID:
25778697
49.

[Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].

Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X.

Rev Neurol. 2015 Feb 16;60(4):164-8. Spanish.

PMID:
25670046
50.

Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

Sastre-Garriga J, Tur C, Pareto D, Vidal-Jordana A, Auger C, Río J, Huerga E, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2015 May;21(6):749-56. doi: 10.1177/1352458514556300. Epub 2014 Nov 12.

PMID:
25392330

Supplemental Content

Loading ...
Support Center